Exclude Patient Type Detail Header
No
Footnote
<b><sup>1</sup> NCCN 2023.</b> Thompson JA, et al. Management of Immunotherapy-Related Toxicities, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Epub 2023 Mar 10. <a href=https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1486><u>Accessed 04/24/2023</u></a>.
<br><br>
<b><sup>2</sup> ASCO 2021.</b> Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>J Clin Oncol.</i> 2021 Dec 20;39(36):4073-4126. <a href=https://ascopubs.org/doi/pdf/10.1200/JCO.21.01440><u>Accessed 04/20/2023</u></a>.
<br><br>
<b><sup>3</sup> SITC 2017.</b> Puzanov I, et al. Managing Toxicities Associated with Immune Checkpoint Inhibitors: Consensus Recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. <i>J Immunother Cancer.</i> 2017 Nov 21;5(1):95. <a href=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697162/pdf/40425_2017_Article_300.pdf><u>Free full-text PDF at PubMed® Central</u></a>. Accessed 04/20/2023.
<br><br>
<b><sup>4</sup> SITC 2021.</b> Brahmer JR, et al. Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Checkpoint Inhibitor-Related Adverse Events. <i>J Immunother Cancer.</i> 2021 Jun;9(6):e002435. <a href=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237720/pdf/jitc-2021-002435.pdf><u>Free full-text PDF at PubMed® Central</u></a>. Accessed 04/20/2023.
<br><br>
<b><sup>2</sup> ASCO 2021.</b> Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>J Clin Oncol.</i> 2021 Dec 20;39(36):4073-4126. <a href=https://ascopubs.org/doi/pdf/10.1200/JCO.21.01440><u>Accessed 04/20/2023</u></a>.
<br><br>
<b><sup>3</sup> SITC 2017.</b> Puzanov I, et al. Managing Toxicities Associated with Immune Checkpoint Inhibitors: Consensus Recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. <i>J Immunother Cancer.</i> 2017 Nov 21;5(1):95. <a href=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697162/pdf/40425_2017_Article_300.pdf><u>Free full-text PDF at PubMed® Central</u></a>. Accessed 04/20/2023.
<br><br>
<b><sup>4</sup> SITC 2021.</b> Brahmer JR, et al. Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Checkpoint Inhibitor-Related Adverse Events. <i>J Immunother Cancer.</i> 2021 Jun;9(6):e002435. <a href=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237720/pdf/jitc-2021-002435.pdf><u>Free full-text PDF at PubMed® Central</u></a>. Accessed 04/20/2023.
Detail Type
Text
Patient Type Detail Header (Long)
<b>Grade 1</b> – Asymptomatic or mild sx<sup>1,2</sup>